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ABSTRACT  
Background: Drug utilization evaluation is an important parameter for the safe, effective and rational use of medications in medical care. 
Alcoholism results in abundant cases of alcohol withdrawal which can prove to be life-threatening if untreated, lorazepam is a drug of choice for 
Alcohol Withdrawal Syndrome and requires close monitoring as its over-dosing or under-dosing is common in case of withdrawal. Objective:  
ensures the safe and rational use of Lorazepam in the management of Alcohol Withdrawal Syndrome. Materials and Method: This prospective, 
observational study was conducted among alcoholic patients admitted in the KC General Hospital, Karnataka, India. Baseline da ta for Clinical 
Institute Withdrawal Assessment for Alcohol revised scale (CIWA-Ar) was collected on the day of admission and the response to lorazepam 
treatment was recorded using the same with respect to the baseline data every 12th hourly after the initial administration until withdrawn. 
Results: Statistical analysis for 72 patients was done using ANOVA to calculate the overall progression of the syndrome with treatment. Among 
72 patients 94.44% were male and 5.55% were female. The mean age of patients reported with AWS was found to be 44.90 years. A  significant 
CIWA-Ar score reduction was observed with a p-value of <0.0001. Conclusion: Our study revealed a strong predominance of male patients with 
alcohol withdrawal syndrome, where maximum patients started consuming alcohol before the age of 20 years. After the administration of 
lorazepam, a significant CIWA-Ar score reduction was observed. 
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INTRODUCTION 
Due to easy availability, liquor has become one of the most 
frequently used products which have had a universal 
effect.[1] According to the DSM-IV TR, Alcoholism, or alcohol 
use disorder (AUD) is the problematic pattern of alcohol use 
leading to clinically significant deterioration or 
psychological distress. Alcoholism results in an estimated 
2.5 million death annually, representing 4% of all 
mortality.[2,3]  
Chronic alcohol consumption leads to dependence and its 
cessation causes withdrawal syndrome, the severity of 
which is not mediated by the age, the extent of dependence, 
drinking patterns or prior number of detoxifications.[4] A 
significant number of AWS patients also have concurring 
liver disease or other medical problems.[5,6]  
Alcohol in small amounts produce behavioral enticement 
and euphoria due to heightened glutamate binding to the 
NMDA receptors. On the other hand, at high concentrations, 
it causes acute intoxication by the exponentiation of GABA 
effects.[7,8] During abstinence, NMDA function is 
augmented20 and GABA transmission reduces resulting in 
withdrawal symptoms.[9] In AWS dopamine level also 
increases, which results in hallucinations and 
hyperarousal.[10] 
The admissible therapy for treating alcohol withdrawal is 
with the use of Benzodiazepines [12] as Gradually tapering, 
Fixed-schedule or Symptom –triggered regimen 
accompanied by Non-pharmacological management by 
implementing early mobilization techniques, providing 
adequate intellectual support and environmental 
stimulation with light and noise control. [13,14]
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Table 1: Alcohol withdrawal syndrome- timeline and stages 
Time Presentation  
6 - 12 hours (mild) 
Quiver, anxiety, GI upset, headache, insomnia,  excessive sweating, palpitations, tachycardia,  
hypertension.  
12 - 24 hours (Moderate) Hallucinations (visual, auditory).  
24 - 48 hours Withdrawal seizures  
48 - 72 hours (Delirium tremens) Alcohol    withdrawal    delirium    (delirium    tremens)[11]  
 
 
Lorazepam is a Benzodiazepine indicated for the 
management of AWS[15] It is promptly absorbed orally and 
reaches maximum concentrations within 2 hours after 
administration. It is mainly metabolized in the liver by 
glucuronic acid conjugation to form inactive lorazepam 
glucuronide and has a t1/2 of 12 hours.16,17] 
Clinical Institute Withdrawal Assessment of Alcohol 
Scale-Revised (CIWA-Ar)  
It is a clinically effective, accurate, brief and simple scale to 
assess the alcohol withdrawal severity. This scale helps to 
monitor the response to treatment and ensures that optimal 
pharmacotherapy can be instituted in patients undergoing 
alcohol withdrawal.[18] Sixty-seven is the maximum possible 
score in the scale[19] and a score of ≥8 but ≤15 indicate a 
probable need for pharmacological treatment. If the score 
goes above fifteen there will be an increased risk of 
confusion and seizure[20] thus, it must be treated 
pharmacologically and vital signs monitoring is also 
important.[16] CIWA-Ar constitutes 10 withdrawal symptoms 
with a rating scale from 0 to 7 for nine of them and 0 to 4 for 
orientation.[21] Most of the symptoms in the scale can be 
rated through simple observation or by asking simple 
questions to assess orientation, headache, and 
visual/auditory or tactile disturbances. The symptoms 
specified within the CIWA-Ar scale are as follows: 
1. Nausea/vomiting 
2. Auditory disturbances 
3. Paroxysmal sweats 
4. Agitation   
5. Tactile disturbances 
6. Tremor  
7. Visual disturbances 
8. Headache 
9. Orientation 
10. Anxiety[22] 
The severity of withdrawal can be assessed at the initial 
stage using the total CIWA-Ar score before initiation of 
pharmacotherapy. CIWA-Ar minimizes the under- and over-
dosing with BZD in the treatment of alcohol withdrawal. 
Most symptoms of alcohol withdrawal subside within four 
days. However, some symptoms, like anxiety and sleep 
disturbance may persist for longer.[23] This 10-item scale 
takes about one minute to complete by the assessor. 
Although it consumes very less time to administer, its 
relevance is still limited in research setting and is a factor 
limiting widespread clinical use.[24] CIWA-Ar is to be 
administered on the admission of the patient followed by 
scheduled hourly scoring until the score falls below 6 on 
four consecutive occasions.   
Drug utilization evaluation 
Drug Utilization Evaluation [DUE] or Medication Use 
Evaluation [MUE], according to WHO is the marketing, 
distribution, prescription and use of drugs in society with 
special prominence on the resulting medical social and 
economic consequences.[25] The purpose of DUE is to ensure 
the judicious, safe and effective use of drugs to improve 
patient health.[26] DUEs can be classified as qualitative and 
quantitative. Qualitative DUE studies are set out to 
determine the rational use of the drug. They require 
qualitative criteria such as duration of treatment, dosage for 
indications, drug of choice and fixed combinations.[27] 
Concurrent DUE studies are performed during the treatment 
course and the ongoing monitoring of drug therapy.[25,26]  
MATERIALS AND METHODS 
This prospective, observational study was conducted among 
72 consecutive AWS patients both male and female admitted 
in the General Medicine department of KC General Hospital, 
Bengaluru, India from September 2018 to February 2019.  
Patients between the age of 20 to 75 with a history of alcohol 
use and withdrawal syndrome prescribed with Lorazepam 
were enrolled in the study and written consent forms were 
obtained, after providing appropriate information. On 
obtaining Informed Consent Document, patient medical 
chart containing information such as demographics, past 
medical and medication, social and family history, 
medication chart, lab data, etc are recorded in the 
specifically prepared data collection forms. AWS patients 
prescribed with lorazepam were assessed for the efficacy 
and safety of the drug. Efficacy assessment of lorazepam was 
done using the CIWA-Ar scale score. Baseline data for CIWA-
Ar was collected on the day of admission. The response to 
lorazepam treatment was recorded using the CIWA-Ar scale 
with respect to the baseline data every 12th hourly after the 
initial administration until withdrawn. Safety assessment of 
lorazepam was done by examining for any drug-related 
errors, adverse events, interactions, etc. using Micromedex. 
Patients were counseled regarding their disease condition 
and alcohol abstinence and were provided with a Patient 
Information Leaflet after ascertaining their understanding. 
Statistical analysis was done using repeated measure 
ANOVA followed by Takis multiple comparison test as the 
posttest to calculate the overall progression of the syndrome 
with treatment. 
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RESULTS  
Gender distribution 
The prevalence of AWS was more among men (94%) than 
women (6%).  
 
Figure 1: Frequency distribution of gender in the study 
population 
Age distribution 
The age distribution of patients with alcohol withdrawal 
cases in the age group of 20-45 constituted 42(58.33%) 
following by 30(41.66%) in the 46-75 age group. 
 
Figure 2: Age distribution 
The onset of alcohol consumption 
The age at which alcohol consumption began varied largely 
between 15-25years (40%) to >46years (7%).         
 
 
Figure 3:   Frequency distribution for the onset of 
alcohol consumption 
Comorbid liver complications 
Out of 72 AWS patients, 45(62.5%) presented with liver 
complications at various stages of alcoholic liver disease and 
27(37.5%) patients with other accompanying diseases. 
Table 2: Comorbid liver conditions 
 Patients Percentage 
AWS with ALD 45 63% 
AWS with other complications 27 37% 
 
Reduction in CIWA-Ar score 
A significant CIWA-Ar score reduction was observed during 
the therapy. Results were obtained using Graph Pad Prism 
Version 5, Repeated measure ANOVA with  
p-value of <0.0001.  
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Figure 4: CIWA-Ar score after Lorazepam administration 
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Time of symptom resolution 
Among 72 patients, on the administration of the CIWA-Ar 
scale, the score reduction corresponded to 10 symptoms of 
alcohol withdrawal. Among these symptoms, most patients 
recovered from nausea and tremors at the 60th hour, At 48th 
and 60th-hour anxiety resolved while the remaining 
symptoms resolved at the 12th hour. 
 
Figure 5: Frequency distribution of the time at which symptoms resolve. 
 
Recovery Distribution 
The maximum recovery was seen at the 60th hour after 
Lorazepam administration with 43 patients followed by 48th 
hour with 9 patients and 84th hour with 8 patients and 96th 
hour with 4 patients, 72nd hour with 3 patients and 36th and 
24th hour with 2 patients each and 120th hour with 1 patient.
 
 
Figure 6: Recovery distribution 
DISCUSSION 
Alcohol withdrawal syndrome is a group of symptoms that 
occur on abruptly stopping after chronic alcohol 
consumption. Lorazepam is a short-acting, lipophilic 
benzodiazepine. It causes an increase of the GABA inhibitory 
effects by allosterically binding to the benzodiazepine 
receptors in its ligand-gated chloride channel of the central 
nervous system (CNS). This leads to cell membrane 
stabilization and hyperpolarization. 
As per the WHO Global status report on alcohol and health, 
2005 men surmount women in case of heavy drinking by 
four to one thus predominantly making them prone to 
alcohol-related problems than women which corresponds to 
result obtained in this study, where among 72 patients, 68 
(94.44%) were male and 4 (5.55%) were females.[28] 
As per the findings by Kolasani PB et al, the average age of 
alcoholic patients was 44.88 and the average age of patients 
enrolled in this study was found to be 44.90 years. This 
result also coincides with the observation by Wetterling T et 
al, 2000 that the severity of AWS is age-independent. [3,5] 
The study coordinated by Grant F.B et al 1997, summarized 
that a reduction of 8% alcohol abuse and 14% dependence 
was observed for every increase in age after onset, thus the 
chances of developing alcohol-related problems are more 
common among people who started at an early age which is 
contradicted in this study, where out of 72 patients, 
29(40.28%) patients started consuming between age of 15-
25years, 30(41.67%) started consuming between the age of 
26-35 years, followed by 8 (11.11%) patients between 36-45 
years and 5(6.94%) started above the age of 46 years. All 
these patients reported alcohol dependence and associated 
withdrawal.[29] 
A majority of liver disease can be contributed to alcohol 
abuse. In our study, 45 (62.5%) Alcohol withdrawal patients 
had accompanying liver complications at various stages of 
ALD and 27 (37.5%) with other problems not related to liver 
functioning. As mentioned by Lorenzo Liggio et al, in their 
review alcoholism is the major factor in liver disease.[16] 
As specified by Makdissi R et al and Asplund AC et al, the 
initial dose is 2-3 mg PO every 8-12 hours not exceeding 
10mg/day. Maintenance dose is 2-6 mg/day. All the patients 
in our study were prescribed with lorazepam (2mg) for 
withdrawal syndrome and evaluated every 12 hrs for 
reduction in symptoms. [30,14] 
Pursuant to Holbrook MA et al and Bayard M et al, we have 
adopted CIWA –Ar scale daily to check the efficacy of 
lorazepam therapy in arresting the withdrawal symptoms. A 
score on this scale lesser than 8 can be treated non-
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pharmacologically while above 8 requires pharmacological 
therapy. [22,31] 
Most symptoms of alcohol withdrawal subside within 4 days 
only a few may remain for longer. The severity of AWS can be 
assessed by CIWA-Ar scale and it checks the progress of 
treatment, wherein a decrease in the score after 
administration of lorazepam shows a positive response as 
recorded by Sullivan TJ et al and Gortney SJ et al, similarly, in 
our study, maximum patients recovered at the 60th hour after 
the administration of Lorazepam with 43(59.72%) 
patients.9(12.5%) patients recovered at the 48th hour, 
8(11.11%) at the 84th hour, 4(5.55%) at the 96th hour 
3(4.16%) at the 72nd hour and 2(2.77%) patients each at the 
24th and 36th hour followed by 1(1.38%) at the 120th hour. 
34,48 
On the administration of the CIWA-Ar scale, score reduction 
among the patients corresponded to 10 symptoms of alcohol 
withdrawal. Among these symptoms, most patients 
recovered from nausea and tremors at the 60th hour. From 
anxiety, at both the 48th and 60th hour while the remaining 
symptoms resolved at the 12th hour but this result 
contravenes with the study result done by S. Manikant et al 
in the utility of CIWA-A in AWS assessment.32 
There was no moderate and severe adverse effect reported 
by the patients. Mild adverse effects like nausea, diarrhea, 
and sedation were reported by some patients and were self-
limiting. No serious or irreversible side effects were 
observed throughout our study. Also, there was no 
significant drug interaction seen in the medication profile. 
To identify the necessity of treatment, the severity of the 
baseline withdrawal manifestations had to be evaluated. The 
scale of 10 items scores the severity of vomiting, tremor, 
nausea, sweating, paroxysmal sweat, visual disturbances, 
anxiety, auditory disturbances, tactile disturbances, 
agitation, and headache. The dose is administered if the score 
is >839 and the scoring is repeated every 12th hour until there 
is a reduction in the score. In our study among all 72 
patients, significant CIWA-Ar scale score reduction was 
observed during the therapy. The results were obtained 
using Graph Pad Prism Version 5, Repeated measure ANOVA 
with a p-value of <0.0001. 
CONCLUSION 
In the treatment of AWS, lorazepam use within the study 
population was found to be safe and effective. A significant 
CIWA-Ar score reduction was observed during the therapy. 
No notable side effects and interactions were encountered in 
any of the patients.  
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